Product
QR-110
2 clinical trials
10 indications
Indication
Leber congenital amaurosisIndication
Leber congenital amaurosis 10Indication
Visual ImpairmentIndication
Vision DisordersIndication
Sensory DisordersIndication
Neurologic ManifestationsIndication
Eye DisordersIndication
HereditaryIndication
Congenital Eye DisordersIndication
Retinal DiseaseClinical trial
An Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneStatus: Completed, Estimated PCD: 2019-10-02
Clinical trial
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneStatus: Terminated, Estimated PCD: 2022-10-03